Semnur Pharmaceuticals, Inc. (SMNR)
OTC Markets OTCPK · USD · Healthcare · Biotechnology
$0.51 (+2.00%) as of
Key statistics
- Market cap
- 117.41M
- EPS (TTM)
- -0.8100
- Dividend yield
- 0.00%
- 52-week range
- 0.1279 – 23.0000
- Beta
- -0.03
- Profit margin
- 0.00%
- Volume
- 200.00
About Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Palo Alto, CA, United States
- Employees
- 5
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.